Celcuity Inc
CELC39.512USD
+1.012+2.63%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.50BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Celcuity Inc Unternehmen
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Unternehmensinformationen
BörsenkürzelCELC
Name des UnternehmensCelcuity Inc
IPO-datumSep 20, 2017
Gegründet am2017
CEOMr. Brian F. Sullivan
Anzahl der mitarbeiter87
WertpapierartOrdinary Share
GeschäftsjahresendeSep 20
Addresse16305 36th Ave N Ste 100
StadtMINNEAPOLIS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl55446-4285
Telefon17633920767
Websitehttps://www.celcuity.com/
BörsenkürzelCELC
IPO-datumSep 20, 2017
Gegründet am2017
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
37.76%
Investment Advisor
19.79%
Individual Investor
12.29%
Investment Advisor/Hedge Fund
10.89%
Private Equity
6.29%
Venture Capital
4.91%
Research Firm
1.98%
Corporation
0.92%
Pension Fund
0.09%
Other
5.09%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
212
36.06M
95.24%
-3.88M
2025Q1
215
36.05M
95.22%
-4.12M
2024Q4
205
35.54M
95.72%
-3.01M
2024Q3
191
34.97M
94.40%
-1.82M
2024Q2
174
33.96M
98.53%
+4.98M
2024Q1
164
26.84M
87.18%
+3.25M
2023Q4
146
21.83M
92.28%
-1.69M
2023Q3
148
21.82M
100.72%
+289.20K
2023Q2
156
20.45M
95.00%
-276.65K
2023Q1
152
18.61M
87.60%
-1.61M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Baker Bros. Advisors LP
4.26M
11.24%
+1.58M
+58.96%
Mar 31, 2025
BVF Partners L.P.
3.47M
9.15%
--
--
Mar 31, 2025
Sullivan (Brian F)
3.02M
7.99%
+8.15K
+0.27%
Apr 14, 2025
Soleus Capital Management, L.P.
2.57M
6.8%
+9.04K
+0.35%
Mar 31, 2025
Perceptive Advisors LLC
2.36M
6.24%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.03M
5.35%
+10.04K
+0.50%
Mar 31, 2025
The Vanguard Group, Inc.
1.67M
4.42%
+20.26K
+1.23%
Mar 31, 2025
Eventide Asset Management, LLC
1.27M
3.34%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.25M
3.3%
--
--
Mar 31, 2025
Laing (Lance G Ph.D.)
1.25M
3.3%
--
--
Mar 17, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
1%
iShares Genomics Immunology and Healthcare ETF
0.93%
ALPS Medical Breakthroughs ETF
0.37%
Tema Oncology ETF
0.26%
iShares Micro-Cap ETF
0.08%
iShares Russell 2000 Growth ETF
0.02%
iShares Russell 2000 ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1%
iShares Genomics Immunology and Healthcare ETF
Anteil0.93%
ALPS Medical Breakthroughs ETF
Anteil0.37%
Tema Oncology ETF
Anteil0.26%
iShares Micro-Cap ETF
Anteil0.08%
iShares Russell 2000 Growth ETF
Anteil0.02%
iShares Russell 2000 ETF
Anteil0.01%
Schwab U.S. Small-Cap ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
